Novartis AG Common Stock (NVS)
R&D Expense Growth
0.69%
Quarterly · Period ending:
NVS R&D Expense Growth
Latest reported0.69%period ending
Latest reported0.69%period ending
NVS Quarterly R&D Growth (QoQ) (0.00% → 0.69%)
Latest values, visible window
High-resolution chart · PNG
NVS r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 0.6894% | |
| -3.4118% | |
| -3.6418% | |
| 7.9575% | |
| 15.2578% | |
| -16.7488% | |
| 18.8127% | |
| 1.0562% | |
| -2.2305% | |
| -5.6876% | |
| -34.5987% | |
| 70.3559% | |
| -10.5243% | |
| 5.4464% | |
| -3.9339% | |
| 1.7614% | |
| 7.6724% | |
| -3.6945% | |
| 1.2185% | |
| -0.8333% | |
| 2.0842% | |
| 0.7715% | |
| 8.7139% | |
| -12.0852% | |
| 18.4951% | |
| -27.7953% | |
| 29.7408% | |
| 7.216% | |
| -10.7873% | |
| -4.1684% | |
| 11.7373% | |
| 0.9878% | |
| 7.2654% | |
| -20.7834% | |
| 11.7463% | |
| 8.5839% | |
| -4.9331% | |
| -16.0604% | |
| 16.1871% | |
| 1.5525% | |
| 7.3003% | |
| -17.4353% | |
| 12.8767% | |
| -0.7253% | |
| 6.7247% | |
| -18.5258% | |
| 17.3994% | |
| -0.7805% | |
| -1.448% | |
| -18.0571% | |
| 21.7058% | |
| -1.3796% | |
| -2.1768% | |
| -12.3617% | |
| 19.6257% | |
| -4.1138% | |
| 2.2371% | |
| -11.415% | |
| 1.9394% | |
| 3.2541% | |
| 9.5521% | |
| -15.5864% | |
| 1.7268% | |
| 34.6012% | |
| -7.0692% | |
| -5.1676% | |
| 17.6986% | |
| 1.2764% | |
| 6.3754% | |
| -7.6336% | |
| -5.5613% | |
| 9.9038% | |
| 5.5556% | |
| -9.3665% | |
| 19.0077% | |
| 1.5043% | |
| 1.7976% | |
| -2.3407% | |
| 9.5442% | |
| 12.0511% | |
| 10.7869% | |
| -23.1658% | |
| 23.5936% | |
| 8.6679% | |
| 0.828% | |
| -11.9125% | |
| 16.1959% | |
| 10.166% | |
| 1.7951% | |
| -13.2784% | |
| 24.3736% | |
| -6.8929% | |
| 11.8624% | |
| -22.9433% | |
| 61.8343% | |
| -5.4545% | |
| 0% | |
| 0% | |
| 0% | |
| -100% |